Management of Membranous Nephropathy after MENTOR

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy

(2019) Barbara Seitz-Polski et al.   Clinical Journal of the American Society of Nephrology

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

(2019) Fernando C. Fervenza et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunological remission in PLA2R-antibody–associated membranous nephropathy: cyclophosphamide versus rituximab

(2018) Anne-Els van de Logt et al.   KIDNEY INTERNATIONAL

Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody

(2018) K. Dahan et al.   KIDNEY INTERNATIONAL

Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy

(2017) Barbara Seitz-Polski et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy

(2017) Jan A.J.G. van den Brand et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

(2016) Karine Dahan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy

(2015) P. Ruggenenti et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy

(2011) L. H. Beck et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous Nephropathy

(2009) Laurence H. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE